IgG and IgA response to SARS-CoV-2 in serum and saliva samples from infected healthcare workers who suffered from relatively mild disease

Published: 15-04-2020 Last updated: 09-04-2024

To investigate the dynamics of IgA and IgG antibody level against SARS-CoV-2 in 86 health care workers with relatively mild symptoms.

Ethical review Approved WMO

Status Pending

Health condition type Viral infectious disorders **Study type** Observational invasive

Summary

ID

NL-OMON49759

Source

ToetsingOnline

Brief title

Investigation into the antibody response to SARS-CoV-2 infection

Condition

- Viral infectious disorders
- Respiratory tract infections

Synonym

COVID-19, new coronavirus

Research involving

Human

Sponsors and support

Primary sponsor: Elisabeth-Tweesteden ziekenhuis

1 - IgG and IgA response to SARS-CoV-2 in serum and saliva samples from infected hea ... 8-05-2025

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: Antibody response, IgA, IgG, SARS-CoV-2

Outcome measures

Primary outcome

IgG and IgA titers

Secondary outcome

sensitivity of Euroimmun assay, the presence of virus neutralizing antibodies

Study description

Background summary

Refer to pag 1 of study protocol

Study objective

To investigate the dynamics of IgA and IgG antibody level against SARS-CoV-2 in 86 health care workers with relatively mild symptoms.

Study design

Observational study

Study burden and risks

4 x venapuncture (6 ml); pain and brusing.

4 x saliva sample; possible irritation of gum

Contacts

Public

Elisabeth-Tweesteden ziekenhuis

Hilvarenbeekseweg 60 Tilburg 5022 GC NL

Scientific

Elisabeth-Tweesteden ziekenhuis

Hilvarenbeekseweg 60 Tilburg 5022 GC NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Healthcare workers with confirmed SARS-CoV-2 infection.

Exclusion criteria

unable to give written informed consent; health care workers that are involved in the design and execution of this study.

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 14-04-2020

Enrollment: 86

Type: Anticipated

Ethics review

Approved WMO

Date: 15-04-2020

Application type: First submission

Review commission: METC Brabant (Tilburg)

Approved WMO

Date: 30-11-2020

Application type: Amendment

Review commission: METC Brabant (Tilburg)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL73713.028.20